Dual Nanobody-Redirected and Bi-Specific CD13/TIM3 CAR T Cells Eliminate AML Xenografts Without Toxicity to Human HSCs

To maintain the bissCART specificity and efficacy, yet reduce toxicity to normal cells including hematopoietic stem cells, investigators generated new anti-TIM-3 nanobodies and constructed new cognate nanobodies-directed CD13/41BB and TIM3/CD3zeta nbiCARTs.